Sanovel Pharmaceutical is a brand that has continuously grown with unfaltering steps since its first establishment and has achieved world-class competencies through its investments in production and R&D. With our stable corporate structure and the relationships built on trust that we have established with all our stakeholders in the healthcare field for more than 30 years, we are delighted to be recognised as a role model in the industry today.
Thanks to its wide product portfolio and production capacity, Sanovel has been amongst the top 3 domestic companies in the turnover ranking of the Turkish pharmaceutical industry virtually every year, according to IMS data. Sanovel can lay claim to superiority in generic drug equivalent manufacturing, but it strengthens that claim by investing in the R & D field and now has an R & D Centre alongside its factory in Silivri, where the annual production capacity is 300 million boxes.
The important steps we have taken by focusing on R&D have today given us the title of the pharmaceutical company holding the highest number of patents. Thanks to this, as well as exporting to three continents, we are able to sell the medication manufactured in our FDA approved line to the USA. We owe this success on an international scale to the high quality standards which we display in our R&D, production and management processes, and on which we have never compromised.
As you know, we are all experiencing a period in which the value of the pharmaceutical sector is now being appreciated in terms of its ability to preserve human life worldwide. We are facing a situation in which the COVID-19 pandemic and other potential epidemics may threaten the future of humanity. I must say that we are proud, under the difficult conditions this era has brought us, to have developed our strengths so as to secure the health of our population and to make our contribution to Turkey becoming a country with self-sufficiency in the provision of pharmaceuticals.
When we take a wider perspective in evaluating the situation we are in, I see that there are important lessons to be learnt for the entire sector. As the pharmaceutical industry, I think we have important opportunities, after the globally disruptive transformation we have experienced, both socially and economically, to reposition ourselves in the eyes of the public for the service we provide and, as a sector, to re-evaluate where we stand. As our Republic approaches the hundredth anniversary since its foundation, I believe we should focus on the future of the "Turkish Medicine" brand and turn to the responsibility of our sector to stake its claim globally. Thanks to the medical schools set up by our country, and the qualified doctors, pharmacists and nursing staff these tremendous schools educate, as well as the investments made in healthcare services, these days we have reached the level in medicine where we may be considered a global brand. At this historical turning point, Turkish pharmaceutical firms, with their advanced capacity to invest in R & D and their global qualifications, should be the most significant supporters of this movement. Sanovel Pharmaceutical is a believer in this goal and positions its brand, which it has built up through constantly adding value, as a participant and driving force behind Turkey's branding goals in the healthcare field.
As we always have, in the spirit of the Sanovel brand, we will undertake our responsibility to be an example and a leader in our sector, along with ever-present dedication to achieving greater goals. Today, with our 1300 employees representing Sanovel spread all across Turkey, we will continue wholeheartedly to contribute to the future development of our sector and the country's economy, whilst remaining loyal to the values of Sanovel that make us who we are.
M. Murat Aktürk